MSH-agonist tripeptide conjugates
The invention relates to a tripeptide conjugate having general formula I, A-AA1-AA2-AA3-NH 2 , wherein A represents the radical corresponding to a monocarboxylic acid with general formula II, HOOC—R, in which: R represents a linear or branched aliphatic radical at C 1 -C 24 , which is optionally substituted by a hydroxyl group and which can comprise one or more unsaturations, preferably between 1 and 6 unsaturations, lipoic acid or the reduced form thereof, dihydrolipoic acid, N-lipoyllysine, or phenylbutyric acid; and AA1, AA2 and AA3, which may be identical or different, represent independently of each other an amino acid selected from His, Phe, Ala, Arg, Lys, Orn, Trp, Nap, Tpi and Tic, on the condition that at least one of AA1, AA2 or AA3 represent Phe, preferably Dphe in the form of enantiomers or diastereoisomers and mixtures thereof, including racemic mixtures.
1. A tripeptide conjugate corresponding to general formula I:
A-AA1-AA2-AA3-NH 2 I
in which
A is a radical corresponding to palmitic acid,
AA1, AA2 and AA3, which may be identical or different, and are, independently of one another, an amino acid chosen from His, Phe, Arg, and Trp, with the proviso that at least one of AA1, AA2 or AA3 is Phe,
in the form of enantiomers or of diastereoisomers, and also mixtures thereof, including racemic mixtures.
2. The tripeptide conjugate as claimed in claim 1 , wherein at least one of AA1, AA2 or AA3 is chosen from the group consisting of Arg, His or Trp.
3. The tripeptide conjugate as claimed in claim 1 , wherein AA2 is DPhe.
4. The tripeptide conjugate as claimed in claim 1 , wherein AA2 or AA3 is Arg.
5. The tripeptide conjugate as claimed in claim 1 , wherein AA1 is His.
6. The tripeptide conjugate as claimed in claim 1 , wherein it is chosen from:
1) Palm-His-DPhe-Arg-NH 2 , and
2) Palm-His-DPhe-Trp-NH 2 .
7. A cosmetic, dermatological or pharmaceutical composition, which contains a tripeptide conjugate as claimed in claim 1 and, optionally, a cosmetically or pharmaceutically acceptable excipient.
8. The tripeptide conjugate as claimed in claim 1 , wherein at least one of AA1, AA2 or AA3 is DPhe.